Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer
This study systematically delineates a novel panel of early-detection biomarkers for CRC and identifies SB-225002 as a repurposed candidate therapeutic agent. The integrative strategy combining multi-cohort transcriptomic analysis, drug-repositioning platforms, molecular docking, and experimental validation offers a feasible framework for discovering clinically actionable biomarkers and small-molecule therapies for CRC.
Authors
- Yulong Xue
- Xiaoxia Cheng
- Lei Zhang
- Yajiang Yu
- Qiming Liao
- Mengzhe Liu
- Xinying Ji
- Zeyuan Yu
Institutions
- Henan University (CN)
- Zhengzhou University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fphar.2025.1723072
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 36.44